Gary R. Morrow, PhD, MS, Susan G. Urba, MD, and Lee S. Schwartzberg, MD
Volume 7, Issue 12 , Supplement 22
Chemotherapy-induced nausea and vomiting (CINV) is a common but debilitating side effect of anticancer therapy. Acute, delayed, and anticipatory CINV can require different approaches, and there have been advances in the prevention of acute CINV in recent years. 5-HT3 and NK-1 receptor antagonists are effective in the prevention of nausea and emesis. Corticosteroids, dopamine receptor antagonists, and cannabinoids have also been introduced in this setting. Clinical guidelines for the management of CINV have been promulgated by the National Comprehensive Cancer Network, the American Society of Clinical Oncology, and the Multinational Association of Supportive Care in Cancer. The etiology of CINV and risk classifications; various treatment approaches, including their mechanisms of action, efficacy findings, and safety issues; and the treatment guidelines are discussed.
BONUS MATERIAL: Corresponding content is provided as a slide library in Powerpoint format.
Download the Complimentary Slide Show

To complete the post-test online:
If any of the lessons shown at right do not contain a CME University link, simply download and read that lesson, and follow the instructions on the post-test page for obtaining CME credit.